Skip to content
Sermorelin Script

A quiet, instrument-grade reading of the sermorelin literature — the GHRH(1-29) fragment read at its receptor: how a peptide that clears the plasma in minutes still conducts the body's own pulsatile growth-hormone signal across the night.

CH·06 / Full study list

Where Can You Check the Sermorelin Studies?

The full entries appear on the online page. A printed copy may not carry that list.

Return to the study findingsSee how Sermorelin works

The online page carries the full study list

Each numbered note points to one entry on the online References page. The entry names the authors, journal, year, and link to the paper.

If your printed copy ends here, the study entries were not included in the printout, so open the online page to see the full list and follow its paper links. The web list fills that gap.

For any number, use its note to check who took part, how long the study ran, and what changed. That keeps a result tied to the right people, drug, and length of study.

  1. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  2. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  7. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. ↗
  8. Bagno L, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(13):10846-10859. ↗
  9. Veldhuis JD, et al. Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men. J Clin Endocrinol Metab. 2004;89(11):5542-8. ↗
  10. Russell-Aulet M, et al. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab. 1999;84(10):3490-7. ↗
  11. Pont L, Alechaga E, Terrero A, et al. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. J Chromatogr A. 2020;1631:461548. ↗
  12. Granata R, Leone S, Zhang X, et al. Growth hormone-releasing hormone and its analogues in health and disease (GHRH-receptor signaling and the GH/IGF-1 axis). Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. Pedrolli F, Morello G, et al. Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models. Cell Death Dis. 2026;17:08699. ↗
  14. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. ↗
  15. Munafo A, Nguyen TX, Papasouliotis O, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European journal of endocrinology. 2005;153:249-56. ↗
  16. Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:32-5; discussion 36. ↗
  17. Khorram O, Laughlin GA, Yen SS Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism. 1997;82:1472-9. ↗
  18. Lanes R, Carrillo E Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. The Journal of pediatric endocrinology. 1994;7:303-8. ↗
  19. Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Hormone research. 1989;31:213-20. ↗
  20. Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:28-30; discussion 31. ↗
  21. Coutinho LFD, DE Oliveira Neves LF, Camilo RP A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. ↗
  22. Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. ↗
  23. Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews. 2026;14. ↗
  24. Esposito S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  25. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. ↗
  26. Ko FY, Chen WP, Lin CY Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33:243-50. ↗
  27. Tuilpakov AN, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995;44:1199-204. ↗
  28. Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94(8):2702-2707. ↗
  29. U.S. Food and Drug Administration Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). FDA Guidance for Industry. 2025. ↗